As global agriculture searches for more sustainable ways to improve crop production, investors are increasingly paying attention to biological technologies that can enhance soil health, boost plant performance, and reduce reliance on traditional chemical inputs.
One emerging agricultural innovator is expanding the commercial reach of its mustard-derived products, advancing an international relationship with Bayer (OTC:BAYRY), and positioning itself to capitalize on growing demand for biological solutions across some of the world’s largest farming markets.
MustGrow Biologics Corp. (TSXV:MGRO/OTCQB: MGROF) is continuing to position itself as a growing player in the agricultural biologicals sector, leveraging mustard-derived technologies aimed at improving soil health, crop nutrition, and crop protection. As global agriculture increasingly seeks sustainable alternatives to conventional chemical inputs, the company is advancing both its commercial product portfolio and strategic industry partnerships while attracting fresh capital to support its next phase of growth.
This article is disseminated in partnership with MustGrow Biologics. It is intended to inform investors and should not be taken as a recommendation or financial advice.
At the centre of MustGrow’s strategy is its proprietary platform of plant-based biological technologies derived from the natural defence mechanisms found in mustard seeds. The company’s research and development efforts focus on developing biological solutions designed to address key agricultural challenges, including soil fertility, pest management, disease control, weed suppression, and postharvest food preservation.
TerraSante expands across key U.S. agricultural markets
MustGrow’s flagship commercial product, TerraSante, has emerged as a key component of the company’s commercialization strategy. The mustard-derived organic biofertility product is designed to support soil and ecological health by providing plant proteins and carbohydrates that feed beneficial soil microbes and improve overall soil function.
In May, MustGrow announced new registration approvals for TerraSante from the agricultural regulators in Texas, Utah, and Montana, expanding the product’s regulatory footprint in the United States. These approvals complement existing registrations and certifications in California, Florida, Georgia, Arizona, Idaho, Oregon, and Washington State, significantly broadening the product’s potential market reach.
The addition of Texas is particularly noteworthy given the state’s large and diverse agricultural economy. Texas produces a wide range of high-value crops, including melons, potatoes, pecans, and grapefruit, creating potential opportunities for products that support soil health and crop productivity. While there is no guarantee TerraSante will directly impact production outcomes in these sectors, the expanded registration provides MustGrow access to a sizeable agricultural market.
TerraSante is sold under Organic OMRI Listed certification and California’s Organic Input Material Program. According to the company, the product contains no artificial additives or preservatives and is intended to promote beneficial microbial activity, nutrient availability, water-use efficiency, root development, and overall plant vigour.
As regenerative agriculture practices continue to gain attention across North America, investors will likely be watching closely to see how quickly TerraSante adoption scales among growers seeking biologically based soil management tools.
Bayer relationship provides significant validation
Beyond its commercial product rollout, one of MustGrow’s most significant developments remains its strategic relationship with global agriculture leader Bayer.
Under an exclusive agreement between the companies, Bayer is evaluating MustGrow’s biological technologies to determine their efficacy and commercial potential across major agricultural regions, including Europe, Asia Pacific, the Middle East, and Africa.
In a media release, the company explained that the agreement grants Bayer rights to use MustGrow’s intellectual property for testing purposes and includes options to acquire exclusive rights to several technology applications, including:
- Preplant soil fumigation
- Bioherbicide applications
- Postharvest potato preservation and sprout inhibition
Importantly, Bayer is responsible for funding and leading the laboratory testing, field development, regulatory activities, and market preparation necessary for potential commercialization within those territories.
For MustGrow, the relationship represents more than a standard commercial arrangement. It serves as third-party validation from one of the world’s largest agricultural companies, while potentially providing exposure to regions that collectively represented an estimated 56 per cent of the global crop protection market.
Meanwhile, MustGrow continues advancing field trials, regulatory programs, and research initiatives in other regions, collaborating with a variety of agricultural, chemical, and food-industry partners.
The broader market opportunity also appears favourable. Demand for biological crop protection products continues to grow as regulators, growers, consumers, and food companies seek alternatives to synthetic chemicals. Industry forecasts have projected strong long-term growth for the global biopesticide sector, driven by organic food demand, sustainability initiatives, and regulatory shifts toward environmentally friendly agricultural inputs.
Building a broader biological technologies platform
While TerraSante currently represents MustGrow’s primary commercial opportunity, the company continues developing a broader technology pipeline built around mustard-derived biological solutions.
MustGrow’s technology platform is focused on creating plant-based biopesticides that target diseases, pests, and weeds using natural compounds found in mustard seeds. According to the company, its technologies have demonstrated consistent efficacy across multiple crops, regions, and growing seasons throughout North and South America.
One additional long-term opportunity cited by analysts is TerraMG, the company’s biological crop protection platform. Although still in earlier stages of development relative to TerraSante, TerraMG could eventually provide another avenue for commercial expansion if development and regulatory milestones are achieved.
New capital supports commercial scale-up
In June, MustGrow strengthened its balance sheet by completing a C$3.74 million non-brokered private placement under the Listed Issuer Financing Exemption (LIFE) framework.
The financing consisted of approximately 7.48 million units priced at $0.50 per unit, with each unit including one common share and one warrant exercisable at $0.70 over a five-year period.
Management indicated that proceeds from the financing will primarily support inventory production for TerraSante as well as general working capital needs. The decision to allocate capital toward inventory production may signal the company’s expectation of growing commercial demand as registrations continue to expand.
For investors, the financing provides MustGrow with additional resources to support commercialization efforts while potentially reducing near-term funding constraints associated with scaling product availability.
Analyst coverage highlights commercialization opportunity
Adding to investor visibility, European research firm GBC AG recently initiated coverage on MustGrow with a BUY rating and a target price of C$2.70 per share.
In its report, GBC described MustGrow as a company operating in an attractive agricultural market segment driven by increasing demand for biological products, regenerative farming practices, and sustainable crop production solutions.
The research firm identified TerraSante as the primary driver of the investment thesis while also highlighting TerraMG and the Bayer relationship as important sources of longer-term upside potential.
GBC forecasts revenue growth from approximately C$4.5 million in fiscal 2026 to C$14.05 million in fiscal 2027 and C$31.56 million by fiscal 2028. The firm also expects improving gross margins as proprietary product sales increase and commercialization scales.
While analyst forecasts are inherently subject to execution risks and market uncertainties, the report underscores the growing attention MustGrow is beginning to receive as it transitions from product development toward broader commercialization.
Investor’s corner
MustGrow Biologics appears to be entering a pivotal stage in its evolution. With TerraSante now approved across an expanding network of U.S. agricultural states, a strategic relationship with Bayer providing international validation and potential commercial pathways, and fresh capital supporting inventory growth and operational expansion, the company is increasingly shifting its focus from development toward market execution.
As with any emerging agricultural technology company, success will ultimately depend on product adoption, regulatory progress, commercial scalability, and the ability to convert technological potential into sustainable revenue growth. However, MustGrow’s expanding footprint and strategic partnerships suggest it is building several avenues for future value creation.
For investors interested in the rapidly growing agricultural biologicals sector, MustGrow may warrant a closer examination. Conducting thorough due diligence on the company’s technology portfolio, commercialization milestones, financial position, competitive landscape, and ongoing relationship with Bayer could provide valuable insight into whether the company is positioned to capitalize on the long-term shift toward more sustainable agricultural solutions.
Find out what the Bullboards are saying about MustGrow Biologics and check out Stockhouse’s stock forums and message boards.